Register Now - Unlocking Longitudinal Patient-Reported Outcomes: The Untapped Value of Specialty Pharmacyocking
|Articles|February 1, 2010

Applied Clinical Trials

  • Applied Clinical Trials-02-01-2010
  • Volume 0
  • Issue 0

Applied Clinical Trials Digital Edition - February 2010

REGULATORY : Avoiding Adverse Event Setbacks in Early Studies TRIAL DESIGN : Proposed Payment Models For the Phase I Volunteer European Pediatric Survey Unveils Research Challenges Also in this issue : FDA Commissioner Wraps Up Her First Year, EU Focuses on Inclusion of Elderly in Trials, Clinical Data Warehouses Stall in Real World, How Pediatric Networks Benefit Children

Articles in this issue

over 16 years ago

Prepare Early for Adverse Events

over 16 years ago

Paying the Phase I Volunteer

over 16 years ago

When Great Ideas Meet the Real World

over 16 years ago

EMEA Sees Benefits for Children

over 16 years ago

Aging Under the Microscope in Europe

over 16 years ago

How to Improve Children's Research

over 16 years ago

Cardiovascular Drug Activity

Related to this article

Where AI Leads in Trial Design—and Where Humans Still Need To
In this video interview, Claire Riches, VP of clinical solutions at Citeline, makes the case for AI as a sophisticated strategic advisor in trial design while arguing that humans must remain in the lead—especially when factors the model can't fully account for are at stake.